Abstract
Purpose
To compare the therapeutic effects and adverse events (AE) of current first-line treatments of advanced RCC, including sorafenib, sunitinib, temsirolimus, and the combination of bevacizumab and IFN-α.
Methods
We performed a meta-analysis of randomized controlled trials of the effectiveness of the five treatments among patients with advanced RCC. The data of progressive disease, objective response rate (ORR), disease control rate (DCR), grade 3/4 AE, progression-free survival (PFS), and overall survival (OS) were extracted to assess therapeutic effects, toxicity, and prognosis, respectively.
Results
Two studies that assessed the combination of bevacizumab with IFN α (n = 1381), one sunitinib (n = 750), one sorafenib (n = 189) and one temsirolimus (n = 416) were included. Sorafenib, sunitinib, temsirolimus (R = 0.35, 95 % confidence interval [CI] 0.26–0.48, P < 0.01), and the combination of bevacizumab with IFN (R = 0.64, 95 % CI 0.42–0.99, P = 0.04) were more effective in controlling tumor progression than IFN. Sorafenib, sunitinib, and temsirolimus do not own advantage in ORR compared with IFN (R = 2.06, 95 % CI 0.53–7.95, P = 0.30), but combination of bevacizumab with IFN showed better results in ORR than IFN (R = 2.56, 95 % CI 1.91–3.42, P < 0.01). Sorafenib, sunitinib, temsirolimus (R = 2.90, 95 % CI 2.23–3.78, P < 0.01), and combination of bevacizumab with IFN (R = 2.14, 95 % CI 1.65–2.78, P < 0.01) were more effective than IFN in DCR. Sorafenib, sunitinib, and temsirolimus had similar rate of grade 3/4 AE as IFN (R = 1.21, 95 % CI 0.96–1.51, P = 0.10). Combined use of bevacizumab and IFN is associated with higher frequency of the AE (R = 2.09, 95 % CI 1.66–2.63, P < 0.01). Sorafenib and sunitinib had similar median PFS (R = 0.67, 95 % CI 0.42–1.08, P = 0.10); temsirolimus had longer median OS (R = 0.82, 95 % CI 0.67–1.00, P = 0.049) as IFN. Combined use of bevacizumab and IFN had longer median PFS (R = 0.68, 95 % CI 0.60–0.76, P < 0.01) and OS (R = 0.86, 95 % CI 0.76–0.97, P = 0.01) than IFN.
Conclusion
Sorafenib, sunitinib, temsirolimus, and the combination of bevacizumab with IFN are more effective in stabilizing disease. Combined use of bevacizumab and IFN is better than sorafenib, sunitinib, and temsirolimus in ORR, PFS, and OS, but associated with higher level of AE.
Similar content being viewed by others
References
Decastro GJ, McKiernan JM (2008) Epidemiology, clinical staging, and presentation of renal cell carcinoma. Urol Clin N Am 35:581–592
Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300
Garcia JA, Cowey CL, Godley PA (2009) Renal cell carcinoma. Curr Opin Oncol 21:266–271
Motzer RJ, Bander NH, Nanus DM (1996) Renal-cell carcinoma. N Engl J Med 335:865–875
van Spronsen DJ, de Weijer KJ, Mulders PF, De Mulder PH (2005) Novel treatment strategies in clear-cell metastatic renal cell carcinoma. Anticancer Drugs 16:709–717
Van Veldhuizen PJ, Hussey M, Lara PN Jr, Mack PC, Gandour-Edwards R, Clark JI et al (2009) A phase II study of gemcitabine and capecitabine in patients with advanced renal cell cancer: southwest oncology group study S0312. Am J Clin Oncol 32:453–459
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134
Motzer RJ, Michaelson MD, Rosenberg J, Bukowski RM, Curti BD, George DJ et al (2007) Sunitinib efficacy against advanced renal cell carcinoma. J Urol 178:1883–1887
Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103–2111
Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281
Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449–456
Kim HL, Belldegrun AS, Freitas DG, Bui MH, Han KR, Dorey FJ et al (2003) Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J Urol 170:1742–1746
Higgins JPT, Green S (2013) Cochrane handbook for systematic reviews of interventions. Version 5.1.0. The Cochrane Collaboration
Higgins JPT, Green S, Cochrane Collaboration (2008) Cochrane handbook for systematic reviews of interventions, vol 21. Wiley-Blackwell, Chichester, p 649
Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560
Escudier B, Bellmunt J, Negrier S, Bajetta E, Melichar B, Bracarda S et al (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28:2144–2150
Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L et al (2010) Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28:2137–2143
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584–3590
Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F et al (2009) Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27:1280–1289
Hutson TE (2011) Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist 16(Suppl 2):14–22
Négrier S, Gravis G, Pérol D, Chevreau C, Delva R, Bay JO et al (2011) Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol 12:673–680
Gollob JA, Rathmell WK, Richmond TM, Marino CB, Miller EK, Grigson G et al (2007) Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 25:3288–3295
Feldman DR, Baum MS, Ginsberg MS, Hassoun H, Flombaum CD, Velasco S et al (2009) Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 27:1432–1439
Jonasch E, Corn P, Pagliaro LC, Warneke CL, Johnson MM, Tamboli P et al (2010) Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 116:57–65
Acknowledgments
Funding for this study was provided by the Technology Development Program of Science & Technology Department of Henan (No. 122102310013). The authors also thank Shijie Zhou and Yi He (Sichuan University, Chengdu, China), who assisted with the preparation and proof reading of data and the manuscript.
Conflict of interest
The authors declare that they have no competing interests.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wang, L., Ma, L., Wang, X. et al. Therapeutic effects and associated adverse events of first-line treatments of advanced renal cell carcinoma (RCC): a meta-analysis. Int Urol Nephrol 47, 617–624 (2015). https://doi.org/10.1007/s11255-015-0932-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-015-0932-1